<div id="readability-page-1"><p>L2 Asset Management LLC lessened its holdings in  Cencora, Inc. (NYSE:COR - Free Report) by 95.1% during the second quarter, according to the company in its most recent 13F filing with the Securities &amp; Exchange Commission. The firm owned 827 shares of the company's stock after selling 15,893 shares during the quarter. L2 Asset Management LLC's holdings in Cencora were worth $248,000 as of its most recent filing with the Securities &amp; Exchange Commission.</p><ul><li>Top 3 S&amp;P 500 Winners in a Losing Market</li></ul><p>Several other institutional investors have also added to or reduced their stakes in the business. Connor Clark &amp; Lunn Investment Management Ltd. boosted its holdings in  Cencora by 115.4% during the 1st quarter. Connor Clark &amp; Lunn Investment Management Ltd. now owns 21,631 shares of the company's stock valued at $6,015,000 after acquiring an additional 11,588 shares during the period.  Nuveen LLC bought a new stake in  Cencora in the first quarter valued at approximately $181,284,000.  Independent Advisor Alliance boosted its stake in shares of  Cencora by 9.5% during the first quarter. Independent Advisor Alliance now owns 1,817 shares of the company's stock valued at $505,000 after purchasing an additional 158 shares during the period.  Public Sector Pension Investment Board grew its holdings in shares of  Cencora by 7.5% in the first quarter. Public Sector Pension Investment Board now owns 23,485 shares of the company's stock worth $6,531,000 after purchasing an additional 1,645 shares during the last quarter.  Finally, Trajan Wealth LLC increased its stake in shares of  Cencora by 2.8% in the first quarter. Trajan Wealth LLC now owns 115,562 shares of the company's stock worth $32,137,000 after buying an additional 3,116 shares during the period. 97.52% of the stock is currently owned by hedge funds and other institutional investors. </p><h2>Analyst Ratings Changes</h2><p>Several brokerages have weighed in on COR. TD Cowen increased their price target on shares of Cencora from $350.00 to $400.00 and gave the company a &#34;buy&#34; rating in a research report on Monday, November 10th. UBS Group increased their target price on shares of Cencora from $380.00 to $415.00 and gave the stock a &#34;buy&#34; rating in a report on Friday, November 7th. Robert W. Baird boosted their price target on Cencora from $355.00 to $395.00 and gave the company an &#34;outperform&#34; rating in a report on Thursday, November 6th. JPMorgan Chase &amp; Co. upped their price target on Cencora from $344.00 to $417.00 and gave the company an &#34;overweight&#34; rating in a research report on Tuesday, November 11th. Finally, Barclays assumed coverage on Cencora in a research report on Monday. They issued an &#34;overweight&#34; rating and a $400.00 price objective on the stock. Nine equities research analysts have rated the stock with a Buy rating and four have assigned  a Hold rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $373.50.</p><ul><li>Walgreens Stock Rally: 4 Reasons WBA Could Be a Strong Buy</li></ul><p><b>Check Out Our Latest Analysis on COR</b></p><h2>Cencora Price Performance</h2><p>COR opened at $337.32 on Wednesday. The firm has a market cap of $65.44 billion, a PE ratio of 42.43, a P/E/G ratio of 1.60 and a beta of 0.63. The stock has a 50-day moving average price of $341.14 and a 200-day moving average price of $310.38. Cencora, Inc. has a 1 year low of $223.92 and a 1 year high of $377.54. The company has a debt-to-equity ratio of 4.32, a current ratio of 0.90 and a quick ratio of 0.55. </p><ul><li>Teva Pharma is the way to play the re-rise of generic drugs </li></ul><p>Cencora (NYSE:COR - Get Free Report) last posted its earnings results on Wednesday, November 5th. The company reported $3.84 EPS for the quarter, topping analysts' consensus estimates of $3.79 by $0.05. Cencora had a return on equity of 227.15% and a net margin of 0.48%.The business had revenue of $83.73 billion during the quarter, compared to analyst estimates of $83.36 billion. During the same quarter last year, the company earned $3.34 EPS. The company's quarterly revenue was up 5.9% compared to the same quarter last year. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS.  Sell-side analysts predict that  Cencora, Inc. will post 15.37 earnings per share for the current fiscal year. </p><h2>Cencora Increases Dividend</h2><p>The firm also recently declared a quarterly dividend, which was paid on Monday, December 1st. Shareholders of record on Friday, November 14th were given a $0.60 dividend. The ex-dividend date was Friday, November 14th. This is a boost from Cencora's previous quarterly dividend of $0.55. This represents a $2.40 annualized dividend and a yield of 0.7%. Cencora's payout ratio is 30.19%. </p><h2>Insider Buying and Selling at Cencora</h2><p>In other news, CEO Robert P. Mauch sold 5,097 shares of the stock in a transaction on Monday, October 20th. The shares were sold at an average price of $326.80, for a total value of $1,665,699.60. Following the completion of the sale, the chief executive officer directly owned 37,940 shares of the company's stock, valued at $12,398,792. This represents a 11.84% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Chairman Steven H. Collis sold 31,350 shares of the firm's stock in a transaction dated Tuesday, September 16th. The shares were sold at an average price of $289.86, for a total value of $9,087,111.00. Following the sale, the chairman directly owned 305,913 shares in the company, valued at approximately $88,671,942.18. This represents a 9.30% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 46,640 shares of company stock worth $14,099,338 in the last quarter. Corporate insiders own  10.80% of the company's stock. </p><h2>Cencora Profile</h2> (Free Report)<p>Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.</p><h2>Recommended Stories</h2><ul><li>Five stocks we like better than Cencora</li><li>3 Warren Buffett Stocks to Buy Now</li><li>Consumers Got Coal, But Santa Dropped Off Big Gains for These 2 Retailers</li><li>Natural Gas Prices Continue To Rally, These Stocks Should Benefit</li><li>10X Gains? These 3 Robotics Stocks Could Explode by 2035</li><li>When to Sell a Stock for Profit or Loss</li><li>Anheuser-Busch Buys BeatBox to Win Over Younger Drinkers</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUNPUg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUNPUg"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Cencora Right Now?</h2><p>Before you consider Cencora, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cencora wasn't on the list.</p><p>While Cencora currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>L2 Asset Management LLC reduced its holdings in Cencora, Inc. by 95.1% in Q2, selling 15,893 shares. Analysts have increased price targets for Cencora, with a consensus rating of "Moderate Buy" and an average target price of $373.50. Cencora's stock opened at $337.32, with a market cap of $65.44 billion. The company reported Q3 earnings of $3.84 EPS, beating estimates, and increased its dividend.</p>

L2 Asset Management LLC Sells 15,893 Shares of Cencora, Inc. $COR